These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 34225490)

  • 1. Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains.
    Wang J; Li D; Perry S; Hilchey SP; Wiltse A; Treanor JJ; Sangster MY; Zand MS
    mBio; 2021 Aug; 12(4):e0044921. PubMed ID: 34225490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model.
    Carreño JM; Strohmeier S; Kirkpatrick Roubidoux E; Hai R; Palese P; Krammer F
    mBio; 2020 Dec; 11(6):. PubMed ID: 33323511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus.
    Santiago FW; Fitzgerald T; Treanor JJ; Topham DJ
    Vaccine; 2011 Nov; 29(48):8888-97. PubMed ID: 21963871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials.
    Ledgerwood JE; Wei CJ; Hu Z; Gordon IJ; Enama ME; Hendel CS; McTamney PM; Pearce MB; Yassine HM; Boyington JC; Bailer R; Tumpey TM; Koup RA; Mascola JR; Nabel GJ; Graham BS;
    Lancet Infect Dis; 2011 Dec; 11(12):916-24. PubMed ID: 21975270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.
    Hoft DF; Lottenbach K; Goll JB; Hill H; Winokur PL; Patel SM; Brady RC; Chen WH; Edwards K; Creech CB; Frey SE; Blevins TP; Salomon R; Belshe RB
    J Infect Dis; 2016 Oct; 214(7):1020-9. PubMed ID: 27443611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.
    de Vries RD; Altenburg AF; Nieuwkoop NJ; de Bruin E; van Trierum SE; Pronk MR; Lamers MM; Richard M; Nieuwenhuijse DF; Koopmans MPG; Kreijtz JHCM; Fouchier RAM; Osterhaus ADME; Sutter G; Rimmelzwaan GF
    J Infect Dis; 2018 Jul; 218(4):614-623. PubMed ID: 29912453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization.
    Khurana S; Coyle EM; Dimitrova M; Castellino F; Nicholson K; Del Giudice G; Golding H
    PLoS One; 2014; 9(4):e95496. PubMed ID: 24755693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies.
    Nakajima R; Supnet M; Jasinskas A; Jain A; Taghavian O; Obiero J; Milton DK; Chen WH; Grantham M; Webby R; Krammer F; Carter D; Felgner PL; Davies DH
    mSphere; 2018 Dec; 3(6):. PubMed ID: 30541779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prime-Boost Vaccination With a Novel Hemagglutinin Protein Produced in Bacteria Induces Neutralizing Antibody Responses Against H5-Subtype Influenza Viruses in Commercial Chickens.
    Sączyńska V; Romanik-Chruścielewska A; Florys K; Cecuda-Adamczewska V; Łukasiewicz N; Sokołowska I; Kęsik-Brodacka M; Płucienniczak G
    Front Immunol; 2019; 10():2006. PubMed ID: 31552018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.
    Mooney AJ; Li Z; Gabbard JD; He B; Tompkins SM
    J Virol; 2013 Jan; 87(1):363-71. PubMed ID: 23077318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.
    Belshe RB; Frey SE; Graham I; Mulligan MJ; Edupuganti S; Jackson LA; Wald A; Poland G; Jacobson R; Keyserling HL; Spearman P; Hill H; Wolff M;
    J Infect Dis; 2011 Mar; 203(5):666-73. PubMed ID: 21282194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.
    Rudenko L; Naykhin A; Donina S; Korenkov D; Petukhova G; Isakova-Sivak I; Losev I; Stukova M; Erofeeva M; Nikiforova A; Power M; Flores J
    Hum Vaccin Immunother; 2015; 11(12):2839-48. PubMed ID: 26697973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
    Kamlangdee A; Kingstad-Bakke B; Osorio JE
    J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA prime and virus-like particle boost from a single H5N1 strain elicits broadly neutralizing antibody responses against head region of H5 hemagglutinin.
    Wang G; Zhou F; Buchy P; Zuo T; Hu H; Liu J; Song Y; Ding H; Tsai C; Chen Z; Zhang L; Deubel V; Zhou P
    J Infect Dis; 2014 Mar; 209(5):676-85. PubMed ID: 23911711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.
    Kongchanagul A; Samnuan K; Wirachwong P; Surichan S; Puthavathana P; Pitisuttithum P; Boonnak K
    Vaccine; 2020 Jan; 38(4):852-858. PubMed ID: 31708176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-year Vaccination.
    Wang W; Chen Q; Ford-Siltz LA; Katzelnick LC; Parra GI; Song HS; Vassell R; Weiss CD
    Clin Infect Dis; 2019 May; 68(12):2067-2078. PubMed ID: 30256912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and antigenic characterization of a computationally-optimized H5 hemagglutinin influenza vaccine.
    Bar-Peled Y; Huang J; Nuñez IA; Pierce SR; Ecker JW; Ross TM; Mousa JJ
    Vaccine; 2019 Sep; 37(41):6022-6029. PubMed ID: 31481254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Next-Generation H3 Influenza Vaccines in Ferrets Pre-Immune to Historical H3N2 Viruses.
    Allen JD; Ross TM
    Front Immunol; 2021; 12():707339. PubMed ID: 34475872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.